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BACKGROUND: Both intestinal permeability and con-
tractility are altered in inflammatory bowel disease.
Little is known about their mutual relation. There-
fore, an in vitro organ bath technique was developed
to investigate the simultaneous effects of inflamma-
tion on permeability and smooth muscle contractility
in different segments of the colon.
Methods and materials: BALB/c mice were exposed
to a 10% dextran sulphate sodium drinking water
solution for 7 days to induce a mild colitis, while
control mice received normal tap water. Intestinal
segments were placed in an oxygenated organ bath
containing Krebs buffer. Permeability was measured
by the transport of the marker molecules
3H-manni-
tol and
14C-polyethyleneglycol 4000. Contractility
was measured through a pressure sensor. Smooth
muscle relaxation was obtained by salbutamol and L-
phenylephrine, whereas contraction was achieved by
carbachol and 1-(3-chlorophenyl)-biguanide.
Results: The intensity of mucosal inflammation in-
creased throughout the colon. Also, regional differ-
ences were observed in intestinal permeability. In
both normal and inflamed distal colon segments,
permeability was diminished compared with prox-
imal colon segments and the non-inflamed ileum.
Permeability in inflamed distal colon segments was
significantly decreased compared with normal distal
segments. Pharmacologically induced relaxation of
smooth muscles did not affect this diminished per-
meability, although an increased motility positively
affected permeability in inflamed and non-inflamed
distal colon.
Conclusions: Inflammation and permeability is in-
versely related. The use of pro-kinetics could counter-
act this disturbed permeability and, in turn, could
regulate the disturbed production of inflammatory
mediators.
Key words: Dextran sulphate sodium, Mice, Inﬂam-
mation, Intestinal permeability, Intestinal motility
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Introduction
Human inflammatory bowel disease (IBD) represents
Crohn’s disease and ulcerative colitis. Despite ex-
tensive research, the aetiology of human IBD remains
unclear. Genetic, environmental and immunologic
factors are probably all involved in the pathogenesis
of IBD.
13
The gut wall of healthy subjects will normally
provide both barrier and transport functions towards
luminal molecules. In human IBD, an impaired
barrier function has been observed.
47 A defective
barrier function increases the exposure of the mucosa
to the gut contents, including bacteria and antigens,
which may induce intestinal inflammation. It remains
to be defined whether this defective barrier function
occurs as the primary or secondary event, and which
mechanisms and pathways are involved.
8,9
In ulcerative colitis, altered gastrointestinal motility
has been described.
10,11 Several clinical studies have
shown that ulcerative colitis patients have a decrease
in motility, which may increase their diarrhoeal
symptoms.
10,11 According to Collins,
12 studies in
animal models clearly indicate a causal relationship
between the presence of mucosal inflammation and
altered sensory-motor function. Moreover, Snape and
Kao
10 observed that a decrease in colonic smooth
muscle myoelectric and contractility response oc-
curred in animals with experimental colitis. In 2,4,6-
trinitrobenzenesulphonic acid (TNBS)-induced colitis
in rats, inflammation-induced changes in smooth
muscle function were observed that might contribute
to the abnormal motility associated with IBD.
13
Information on the intestinal barrier function can
be obtained by monitoring urinary excretion of orally
administered test markers. Several intestinal perme-
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21ability tests are operational in clinical practise and
research.
Ideal intestinal permeability markers should be
biochemically inert and cross the intestinal epithe-
lium by non-mediated diffusion through defined
pathways.
14,15 Frequently used markers are the
cylindrical polymer polyethylene glycol (PEG) 400
with a cross-sectional diameter of 5.3 A ˚, the globular-
shaped sugar alcohol mannitol with a cross-sectional
diameter of 6.7 A ˚, and
51Cr-labeled ethylenediamine
tetraacetic acid with a cross-sectional diameter of
approximately 11 A ˚.
1618 Instead of PEG 400, which
has a similar size as mannitol, PEG 4000 has also been
used, with a cross-sectional diameter of more than 10
A ˚.
The relation between colonic inflammation, in-
flammatory mediators, altered permeability and
changed motility is not yet fully elucidated. Our aim
was to investigate the effects of two different agonists
on smooth muscle relaxation, namely salbutamol (b2-
agonist), and l-phenylephrine (a1-agonist), and the
effects of two different smooth muscle contracting
agonists, namely carbachol (muscarinic receptor
agonist) and 1-(3-chlorophenyl)-biguanide (5-HT3-
agonist). Contractile activity and transmural perme-
ability were measured simultaneously in an organ
bath as described previously.
19 The dextran sulphate
sodium (DSS) model to induce a mild colitis in mice,
as described by Okayasu et al.,
20 has been modified
and extensively investigated as described pre-
viously.
2125
Materials and methods
Animals
The experiments were conducted with female ado-
lescent BALB/c mice (20/22 g; IFFA Credo, France).
Animals were kept individually on chopped wood
bedding in polystyrene cages under a 12 h day/night
cycle at 20/228C. Mice were permitted free access to
a standard mouse chow (Hope Farms, Woerden, The
Netherlands) and 10% (w/v) DSS supplemented or
normal tap water. The experiments were carried out
after approval of the Ethics Committee for the use of
experimental animals of the Erasmus university
Medical Centre (protocol 118-00-02).
Experimental design
Mice received 10% DSS (molecular weight 500 kDa,
sulphur content 179 /1%; Pharmacia Biotech AB,
Uppsala, Sweden) added to their drinking water to
induce colitis. Controls received normal tap water
throughout the whole study. Animals were killed by
cervical dislocation after drinking DSS for 7 days.
Before sacrifice, mice were 20 h deprived from food.
Immediately after sacrifice, the intestinal segments
were used for in vitro permeability and contractility
experiments. The effect of smooth muscle relaxation
and contraction, induced by various receptor ago-
nists, on intestinal permeability was tested. In the first
series of experiments, salbutamol and 1-(3-chloro-
phenyl)-biguanide were used to induce smooth
muscle relaxation and contraction, respectively,
while L-phenylephrine and carbachol were used for
the same purpose in another series of experiments.
Drugs
Salbutamol (a specific b2-adrenoceptor agonist, 10
2
M; generous gift of Glaxo Wellcome, UK), 1-(3-
chlorophenyl)-biguanide (a specific 5-HT3 receptor
agonist, 10
4 M; lot number 3067A, ICN, Aurora, OH,
USA), L-phenylephrine (an a1-adrenoceptor agonist,
3/10
4 M; lot number 115H0665, Sigma, St Louis,
MO, USA) and carbachol (a muscarine receptor
agonist, 10
1 M; lot number 35H2516, Sigma) were
used. All compounds were dissolved in distilled
water and stored at 48C until use.
Tissue preparation
After the mice were killed, the intestines were
removed from the abdominal cavity. One segment
of the ileum adjacent to the caecum, a proximal colon
and a distal colon segment were taken and immedi-
ately immersed in standard Krebs buffer (pH 7.4),
containing 118 mM of NaCl, 4.7 mM of KCl, 2.5 mM of
CaCl2/2H2O, 1.2 mM of MgSO4/7H2O, 1.2 mM of
KH2PO4, 25 mM of NaHCO3 and 8.3 mM of glucose.
The experimental ex vivo model used in this study
has been described previously.
19 In short, each end
of an intestinal segment was directly cannulated with
stainless-steel cannulas and mounted horizontally in
a 5-ml double-walled Perspex organ bath. The organ
baths, warmed to 378C and filled with standard Krebs
buffer, were continuously gassed with carbogen (95%
O2 and 5% CO2). Next the intestinal lumen was filled
with standard Krebs buffer, containing the marker
molecules
3H-mannitol (NEN Life Science Products,
Hoofddorp, The Netherlands) and
14C-PEG 4000
(Amersham Life Science, Hertogenbosch, The Neth-
erlands); about 500,000 dpm/ml for each labelled
marker. The distal cannula was connected to a low-
pressure sensor (De ´pex, De Bilt, The Netherlands),
which measures the pressure difference between a
passive port, set at 15 mmHg, and the active port. The
signal was recorded by Multiple Channel Registration
computer-software. The pressure detection range
was 159 /9 mmHg.
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Permeability measurements started at t/0 by repla-
cing the organ bath fluid with 5 ml of fresh,
carbogenated Krebs buffer. Every 15 min, 2 ml
samples were taken in duplicate from the serosal
reservoir for marker analysis, directly followed by
exchange of the organ bath fluid. This procedure was
continued for 60 min. Samples were collected in 20-
ml Econo glass vials (Packard Instrument BV, Gro-
ningen, The Netherlands) and 8 ml of scintillation
fluid (Pico-Fluor 15; Packard Instrument BV) was
added. Each vial was counted for radioactivity by a
multi-channel b liquid scintillation counter (1500 TRI-
CARB Liquid Scintillation Analyser; Packard Instru-
ment BV). The
14C-PEG 4000/
3H-mannitol (P/M) ratio
was calculated at each time point and standardised
with the P/M ratio of the filling buffer at t/0t o
perform statistical analysis. Due to the marked
difference in molecular size between PEG 4000 and
mannitol, a diminished P/M ratio also means a
diminished permeability.
Contractility measurements in vitro
Running parallel with the permeability measure-
ments, contractility was monitored by measuring
the intraluminal pressure (mmHg) of each intestinal
segment. At t/0 min, a control period started by the
application of saline was monitored. At t/15 min,
smooth muscle relaxation was induced in segments
of controls and DSS-treated mice by adding a single
dose of 50 ml of salbutamol (10
2 M) to the organ
bath directly after buffer exchange. At t/30 min,
smooth muscle contraction was induced following
the same procedure with a single dose of 50 mlo f5 -
HT3 agonist (1-(3-chlorophenyl)-biguanide, 10
4 M).
In an additional series of experiments, we tested
contractility in the same way and at the same time-
points with single doses of 50 mlo fL-phenylephrine
(3/10
4 M) and 50 ml of carbachol (10
1 M) to
induce relaxation and contraction, respectively. After
the experiment, the recordings of the intraluminal
pressure were evaluated and intestinal contractility
was expressed as the number of contractions per 15
min interval.
Macroscopy and histology
Upon sacrifice, the animal and the removed intestines
were macroscopically examined. Signs of inflamma-
tion were scored in a blind fashion. The macroscopic
score ranged from 0 to 12, which represents the sum
of scores for diarrhoea (0/solid stool consistency,
1/semi-solid stool consistency, 2/watery stools),
bloody stool (0/none, 1/positive), appearance of
the skin (0/shining, 1/dull, 2/hair loss), loco-
motion (0/lively, 1/languid), colon colour (0/
pink, 1/light red, 2/dark red), distension (0/
none, 1/distinctly), appearance of the colon (0/
normal, 1/thickened) and weight gain (0/ /5%,
1/0/5%, 2/weight loss).
Histological analysis was performed with pieces of
the ileum and of the proximal and distal colon. The
pieces were fixed in a pH 7-buffered 3.6% formalde-
hyde solution (Lansberg-Rotterdam BV, Uden, The
Netherlands) and embedded in paraffin wax. Sec-
tions cut at 5 mm thickness and stained with
haematoxylin and eosin were examined under a light
microscope using a 250/ magnification.
Statistical analysis
The data are presented as mean9 /standard error of
the mean. The statistical significance was determined
by non-parametric methods. pB/0.05 was considered
statistically significant.
Results
DSS-induced inflammation
After drinking a solution of 10% dextran sodium
sulphate for 7 days, BALB/c mice developed clinical
signs of colonic inflammation (Table 1). The overall
macroscopic score in the DSS-treated mice was
significantly increased compared with controls (pB/
0.001). This was mainly reflected by the occurrence
of bloody stools, diarrhoea and weight loss. Bloody
stools appeared in 83% of the DSS-exposed animals
versus none of the controls and diarrhoea was
present in 92% of the DSS-treated mice. In addition,
during DSS exposure animals lost a considerable
amount of weight, while controls slightly gained
weight.
The degree of inflammation reflected by histology
showed regional differences between the intestinal
segments. The ileum was not affected by DSS,
whereas aborally an increasing damage in inflamed
colonic segments was observed.
Intestinal contractility
Recording of the intestinal motility resulted in ex-
pected contractility patterns in the control and
inflamed segments of the small intestine and colon
during pharmacological exposure (tracings not
shown). Smooth muscle contractility was measured
as the intraluminal pressure, while the agents were
added at the serosal side of the intestinal segments to
influence smooth muscle activity. Relaxation was
registered as a pressure decline, and contraction as
a pressure rise. In the intestinal segments of both
control and DSS-treated mice, final concentrations of
3/10
6 M L-phenylephrine attenuated the smooth
Intestinal inflammation, motility and permeability
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3 M
carbachol induced strong contractions.
In an additional experiment, 10
4 M salbutamol
and 10
6 M 1-(3-chlorophenyl)-biguanide were used
with the same purpose. Salbutamol suppressed
smooth muscle contractility whereas biguanide in-
duced contractions (Table 2).
The exact amount of circular smooth muscle
relaxation or constriction could not be derived from
the pressure transducers. The intestinal activity of
each segment, however, could be expressed as the
number of spontaneous contractions during pharma-
cological exposure (Figs. 1 and 2, top panels). In the
ileum, which served as the ultimate control, the
frequency of contraction was low compared with
the proximal and distal colon segments. An increased
contractility was found in the presence of either
carbachol or biguanide. No change in the frequency
of contraction was observed in the inflamed colon
compared with control segments during any pharma-
cological exposure. In the proximal colon of control
mice, phenylephrine significantly reduced the num-
ber of contractions compared with the saline exposed
time interval. Subsequently, carbachol exposure sig-
nificantly increased the number of smooth muscle
contractions.
Intestinal permeability
Simultaneously with contractility, the ex vivo perme-
ability was measured from the luminal side towards
serosal side of the intestinal wall with
14C-PEG 4000
and
3H-mannitol molecules. To reach the serosal side
of the intestinal wall, both markers had to cross the
epithelium, the lamina propria, and also the adjacent
circular and longitudinal muscle layers of the muscu-
laris externa and the serosa. Transmural permeation
is expressed as the P/M ratio of the large PEG 4000
and the small mannitol molecule (Figs. 1 and 2,
bottom panels).
In the ileum, exposure to phenylephrine, carba-
chol, salbutamol and biguanide have no effects on
the P/M ratios both in controls and DSS-exposed
mice. The P/M ratio of the ileum segments, however,
was higher compared with the proximal and distal
colon segments as a result of a greater transport of
mannitol in the colon.
In the inflamed distal colon, permeability was
significantly decreased after both phenylephrine-
induced relaxation and carbachol-induced contrac-
tion (Fig. 2, right bottom panel), compared with
saline-exposed interval and control measurements
(Fig. 3).
Discussion
Currently, several animal models are used in inflam-
matory bowel disease research. In 1990, Okayasu et
al.
20 developed a method to induce colitis in mice by
the administration of DSS (MW 54 kDa) via their
drinking water. The DSS model used in our study was
adapted from this method. We used a DSS variant
with a higher molecular mass (500 kDa) and ob-
served comparable macroscopic and histologic ef-
fects. DSS colitis is easily induced and the DSS model
is known as a reproducible method in which colitis
appears with changes corresponding well to those of
human ulcerative colitis
20,26. In our hands, adminis-
tration of 10% DSS to BALB/c mice during 7 days
induced a mild colitis. This was mainly reflected by
the appearance of bloody stools, diarrhoea and
weight loss. Histologic examination of the intestinal
tissue showed a focal and superficial inflammation.
An influx of inflammatory cells in the lamina propria
and disturbed crypt architecture was observed in the
colon, while the ileum was histologically not affected
by DSS exposure.
In general, alterations in intestinal permeability are
studied in flat tissue sheets mounted in Using
chambers
27 or with in vivo perfusion models,
28 while
alterations in contractility are mostly examined with
tissue strips vertically mounted in organ baths.
22,29 In
the ex vivo method used for our study, permeability
was monitored transmurally from the luminal to-
wards the serosal side. Transmural permeability has
Table 1. Macroscopic degree of inﬂammation in DSS-induced colitis in mice
Group n Macroscopic score
(mean9 /SEM)
Bloody stools Diarrhoea % weight change
(mean9 /SEM)
Control 12 1.69 /0.3 0/12 1/12  /1.49 /0.6
DSS 12 6.59 /0.4* 10/12* 11/12*  /13.69 /1.8*
Table 2. Overview of contractile activities and number of movements of colonic segments induced by pharmacological
intervention
Salbutamol (b2) Phenylephrine (a1) Carbachol (muscarine) Biguanide (5-HT3)
Contractility Relaxation Relaxation Contraction Contraction
Movements Decrease Decrease  / No effect/increase
F. J. Zijlstra et al.
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30,31
Intestinal loops are everted and filled with fluid. In
this method, the mucosal to serosal transport of
permeability markers is measured to assess changes
in the intestinal barrier function. In our model the
intestinal segments are not everted, but directly filled
with buffer containing the marker molecules. The
large PEG 4000 molecule was used to mimic the
macromolecular permeability of dietary antigens and
bacterial products. Seidman et al.
32 have shown that
PEG 4000 is a suitable permeability marker, which is
neither degraded by intestinal bacteria nor metabo-
lised after absorption in the intestine. PEG 4000 and
mannitol are both used as paracellular permeability
probes.
33,34 Large molecules like PEG 4000 are
thought to diffuse via large pores at the crypt
membrane, while the permeation pathway of small
molecules can be both via small pores at the villus
FIG. 1. Mean effects of salbutamol (10
4 M) and biguanide (10
6 M) on contractility measured as the number of movements
in intestinal segments from the ileum, proximal colon and distal colon in control mice (n/6; top left panel) and DSS-induced
inﬂammation (n/6; top right panel), and on permeability determined by the PEG 4000/mannitol ratio in the same intestinal
segments of control mice (bottom left panel) and DSS-induced inﬂammation (bottom right panel). * pB/0.05 versus saline.
FIG. 2. Mean effects of phenylephrine (3/10
6 M) and carbachol (10
3 M) on contractility measured as the number of
movements in intestinal segments from the ileum, proximal colon and distal colon in control mice (n/6; top left panel) and
DSS-induced inﬂammation (n/6; top right panel), and on permeability determined by the PEG 4000/mannitol ratio in the
same intestinal segments of control mice (bottom left panel) and DSS-induced inﬂammation (bottom right panel). * pB/0.05
versus saline.
Intestinal inflammation, motility and permeability
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brane.
13,15 Thus, inflammatory damage of the intest-
inal barrier will result in an altered P/M ratio.
14
In the present study, a significantly decreased P/M
ratio was demonstrated in the inflamed distal colon
compared with control. In the less inflamed proximal
segment, permeability was not altered. Pharmacolo-
gical-induced relaxation and contraction of smooth
muscles had minor effects on permeability. Only a
significant increase in permeability was observed
after application of carbachol to both inflamed and
control distal colon segments. In earlier studies we
found an aboral increase of longitudinal smooth
muscle contraction induced by carbachol in non-
inflamed colon, whereas this was abolished in
inflamed colonic tissue.
22 In the experimental set-
up of the herewith-used model, smooth muscle
activity is mainly resulting from the circular instead
of the longitudinal intestinal muscle layer.
22 Although
for all compounds used a clear relaxation or contrac-
tion was observed through registration of the intra-
luminal pressure, the frequency of contraction was
less influenced by these agonists. In general, from
our observations it could be concluded that pharma-
cologically induced reduction in motility, reflected by
the number of movements, circular and longitudinal
smooth muscle relaxations, does not directly alter
intestinal permeability. On the other hand, the build-
up pressure by constrictive agonists such as carba-
chol and biguanide slightly increased permeability in
distal colon segments.
Intestinal permeability is not only influenced by
the epithelial barrier, but also by the endothelial
barrier.
35 In our experimental set-up the latter path-
way is not involved, however, as blood flow in the
isolated intestinal segment is absent. Recently, we
investigated intestinal blood flow in BALB/c mice by
means of radioactive microspheres.
36 Interestingly,
there was a stepwise decline in the intestinal blood
flow in control mice from the upper small intestine
down to the distal colon. In DSS-induced inflamma-
tion, however, blood flow in the middle and distal
colon was increased compared with control mice.
Inflammatory mediators locally formed
19,21,23,24 could
be cleared more rapidly by an increased blood flow,
considering systemic effects will be negligible. Attri-
butive to this self-regulating effect, the additional use
of pro-kinetics or volume expanders could be
beneficial to counteract the disturbed permeability
and, in turn, could regulate the influx and activation
of inflammatory cells and the subsequent production
of proinflammatory mediators, possibly resulting in a
recovered colitis.
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